NASDAQ:MRSN - Mersana Therapeutics Stock Price, Forecast & News

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.35) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.02. The company earned $0.84 million during the quarter, compared to the consensus estimate of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. View Mersana Therapeutics' Earnings History.

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Mersana Therapeutics.

4 analysts have issued 12-month price objectives for Mersana Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Mersana Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 49.1% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

News stories about MRSN stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mersana Therapeutics earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Mersana Therapeutics.

Mersana Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,070,000 shares, an increase of 29.5% from the December 15th total of 826,400 shares. Based on an average daily trading volume, of 324,600 shares, the short-interest ratio is currently 3.3 days. Approximately 3.3% of the shares of the company are sold short. View Mersana Therapeutics' Current Options Chain.

Some companies that are related to Mersana Therapeutics include Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA), Intra-Cellular Therapies (ITCI), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), TG Therapeutics (TGTX), BELLUS Health (BLUSF), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV) and Endonovo Therapeutics (ENDV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Dynavax Technologies (DVAX), ACADIA Pharmaceuticals (ACAD), Eyepoint Pharmaceuticals (EYPT), ImmunoGen (IMGN), Kala Pharmaceuticals (KALA), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Immunomedics (IMMU).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.07%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

MRSN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $8.05.

Mersana Therapeutics has a market capitalization of $385.47 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

The official website for Mersana Therapeutics is http://www.mersana.com/.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]